Study

No. of

patients

Design

Type of treatment

CR

(%)

PR

(%)

Median survival

(months)

1-y OS

(%)

Our study

62

Prospective

3DCRT to PVTT

8.5%

31.9%

All patients: 8.2

Responders: 12.5

Non responders: 8

All patients: 25.2

Responders: 56.5

Non responders: 17.2

Rim et al. (2012)

45

Retrospective

3DCRT to PVTT ± Liver tumor

6.7%

55.6%

All patients: 11.2

Responders: 16.7

Non responders: 8

Responders: 63.7

Non responders: 28

Hou et al. (2012)

128

Retrospective

3DCRT to PVTT

20.8%

33.3%

8.2

-

Huang et al. (2009)

326

Retrospective

3DCRT/IMRT to PVTT

5.8%

19.4%

All patients: 4

CR: 13.3

PR: 11.6

SD: 9

PD: 4.5

-

Toya et al. (2007)

38

Retrospective

3DCRT to PVTT ± Liver tumor

15.8%

28.9%

9.6

39.4

Lin et al.

(2006)

22/21

Prospective

SBRT/3DCRT to PVTT

Crude response 75%/83%

6/6.7

-

Kim et al.

(2005)

59

Retrospective

3DCRT to PVTT and Liver tumor

6.8%

39%

Responders: 10.7

Non responders: 5.3

Responders: 40.7

Non responders: 25